X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aventis Pharma with Sun Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs SUN PHARMA - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA SUN PHARMA SANOFI INDIA/
SUN PHARMA
 
P/E (TTM) x 30.0 15.0 199.8% View Chart
P/BV x 5.3 3.5 150.1% View Chart
Dividend Yield % 1.7 0.2 784.5%  

Financials

 SANOFI INDIA   SUN PHARMA
EQUITY SHARE DATA
    SANOFI INDIA
Dec-16
SUN PHARMA
Mar-16
SANOFI INDIA/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs4,5601,201 379.8%   
Low Rs4,400706 622.9%   
Sales per share (Unadj.) Rs1,028.5117.5 875.5%  
Earnings per share (Unadj.) Rs129.019.6 658.1%  
Cash flow per share (Unadj.) Rs186.023.8 781.2%  
Dividends per share (Unadj.) Rs68.001.00 6,800.0%  
Dividend yield (eoy) %1.50.1 1,447.4%  
Book value per share (Unadj.) Rs753.6130.5 577.5%  
Shares outstanding (eoy) m23.032,406.60 1.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.48.1 53.7%   
Avg P/E ratio x34.748.7 71.4%  
P/CF ratio (eoy) x24.140.1 60.1%  
Price / Book Value ratio x5.97.3 81.4%  
Dividend payout %52.75.1 1,033.3%   
Avg Mkt Cap Rs m103,1742,294,813 4.5%   
No. of employees `0003.614.7 24.6%   
Total wages/salary Rs m3,59247,971 7.5%   
Avg. sales/employee Rs Th6,537.719,169.8 34.1%   
Avg. wages/employee Rs Th991.43,253.0 30.5%   
Avg. net profit/employee Rs Th819.83,197.9 25.6%   
INCOME DATA
Net Sales Rs m23,686282,697 8.4%  
Other income Rs m7086,170 11.5%   
Total revenues Rs m24,394288,867 8.4%   
Gross profit Rs m5,28183,239 6.3%  
Depreciation Rs m1,31310,135 13.0%   
Interest Rs m154,769 0.3%   
Profit before tax Rs m4,66174,505 6.3%   
Minority Interest Rs m0-11,126 0.0%   
Prior Period Items Rs m0-19 0.0%   
Extraordinary Inc (Exp) Rs m0-6,852 0.0%   
Tax Rs m1,6919,349 18.1%   
Profit after tax Rs m2,97047,159 6.3%  
Gross profit margin %22.329.4 75.7%  
Effective tax rate %36.312.5 289.1%   
Net profit margin %12.516.7 75.2%  
BALANCE SHEET DATA
Current assets Rs m15,673308,646 5.1%   
Current liabilities Rs m6,678132,477 5.0%   
Net working cap to sales %38.062.3 60.9%  
Current ratio x2.32.3 100.7%  
Inventory Days Days7683 91.6%  
Debtors Days Days2288 25.4%  
Net fixed assets Rs m8,098133,606 6.1%   
Share capital Rs m2302,407 9.6%   
"Free" reserves Rs m17,088266,909 6.4%   
Net worth Rs m17,356314,042 5.5%   
Long term debt Rs m031,167 0.0%   
Total assets Rs m25,400542,196 4.7%  
Interest coverage x311.716.6 1,875.3%   
Debt to equity ratio x00.1 0.0%  
Sales to assets ratio x0.90.5 178.9%   
Return on assets %11.89.6 122.7%  
Return on equity %17.115.0 114.0%  
Return on capital %26.917.8 151.8%  
Exports to sales %24.514.0 175.0%   
Imports to sales %28.03.1 890.5%   
Exports (fob) Rs m5,80139,572 14.7%   
Imports (cif) Rs m6,6278,882 74.6%   
Fx inflow Rs m7,14542,171 16.9%   
Fx outflow Rs m6,84621,583 31.7%   
Net fx Rs m29920,588 1.5%   
CASH FLOW
From Operations Rs m3,22667,694 4.8%  
From Investments Rs m-1,555-44,549 3.5%  
From Financial Activity Rs m-1,818-19,243 9.4%  
Net Cashflow Rs m-1473,902 -3.8%  

Share Holding

Indian Promoters % 0.0 63.7 -  
Foreign collaborators % 60.4 0.0 -  
Indian inst/Mut Fund % 14.4 5.1 280.7%  
FIIs % 14.6 23.0 63.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 8.3 126.5%  
Shareholders   15,184 133,026 11.4%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   FULFORD INDIA  VENUS REMEDIES  IPCA LABS  WOCKHARDT LTD.  SUVEN LIFE  

Compare SANOFI INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Infosys Woes, Insurance IPOs and Top Stocks in Action(Pre-Open)

On Monday, the share markets in India slumped in the final hours of trade and finished the day in red.The BSE Sensex closed lower by 266 points to end at 31,259.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Sun Pharma: USFDA Observations Post Good Quarterly Performance (Quarterly Results Update - Detailed)

Dec 12, 2016

Sun Pharma has announced its September quarter (2QFY17) results. The company has reported 13.2% YoY growth in sales and a growth of 117% in the net profits. Here is our analysis of the results.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Aug 21, 2017 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA - WOCKHARDT LTD. COMPARISON

COMPARE SANOFI INDIA WITH

MARKET STATS